key: cord-0779684-ukt55ub5
authors: Sazed, Saiful Arefeen; Kibria, Mohammad Golam; Hossain, Mohammad Sharif; Zamil, Md Fahad; Adhikary, Pranob Chandra; Hossain, Mohammad Enayet; Ahmed, Dilruba; Haque, Rashidul; Alam, Mohammad Shafiul
title: Clinical Evaluation of a New Antigen-Based COVID-19 Rapid Diagnostic Test from Symptomatic Patients
date: 2021-12-08
journal: Diagnostics (Basel)
DOI: 10.3390/diagnostics11122300
sha: 5210add168e0be917a17178f80cfb8fc5d6ba963
doc_id: 779684
cord_uid: ukt55ub5

Accurate diagnosis at the right moment is the prerequisite for treatment of any disease. Failure to correctly diagnose a disease can result in highly detrimental effects, unmistakably a crucial factor during the COVID-19 pandemic. RT-PCR is the gold standard for COVID-19 detection while there are other test procedures available, such as LAMP, X-Ray, and ELISA. However, these tests are expensive, require sophisticated equipment and a highly trained workforce, and multiple hours or even days are often required to obtain the test results. A rapid and cheap detection system can thus render a solution to the screening system on a larger scale and be added as an aid to the current detection processes. Recently, some rapid antigen-based COVID-19 tests devices have been developed and commercialized. In this study, we evaluated the clinical performance of a new rapid detection device (OnSite(®) COVID-19 Ag Rapid Test by CTK Biotech Inc., Poway, CA, USA) on COVID-19 symptomatic patients (n = 380). The overall sensitivity and specificity were 91.0% (95% CI: 84.8–95.3%) and 99.2% (95% CI: 97.1–99.9), against gold standard RT-PCR. The kit was capable of detecting patients even after 06 days of onset of symptoms and the sensitivity can be maximized to 98% in samples with an average RT-PCR Ct ≤ 26.48, demonstrating a high potential of the kit for clinical diagnosis of symptomatic patients in healthcare facilities.

Thousands of people are losing their lives every day due to the global COVID-19 pandemic, and fast and accurate diagnosis is still a barrier in most countries [1] . While this pandemic is not under control, it has already caused over 232 million confirmed cases and more than 4.7 million deaths worldwide [2] . Lack of expertise, false-negative results, and a relative scarcity of convenient diagnostic methods, worsen the situation [3] . Moreover, asymptomatic individuals are roaming around the communities, acting as a potential virus reservoir and thus posing a significant threat to community-level transmission [4, 5] . Multiple vaccines have been deployed worldwide and others are in development, but still not readily available to everyone, and especially with the constant appearance of new viral variants, there are chances of transmission even after getting vaccinated [6] [7] [8] .

Although, until now, no confirmed medicine can effectively treat patients infected with the SARS-CoV-2 virus [9, 10] , safe distancing, proper hygiene and early supportive treatment during active infection may often help prevent worst-case scenarios for an individual, as well as reduce community transmission [11] . Additionally, to understand more about the etiology of the disease, better testing accuracy and repeatability are needed to effectively screen people and take the necessary measures. Aggressive screening will contribute to the Diagnostics 2021, 11, 2300 2 of 10 containment of the virus as well as community transmission [12, 13] . Optimum solutions for mass-level screening are therefore urgently needed.

Several methods have been invented around the globe, including the RT-PCR, loop mediated isothermal amplification (LAMP), enzyme-linked immunosorbent assay (ELISA), rapid diagnostic test (RDT), radiological evaluation, and some mobile applications [14] [15] [16] [17] [18] . Every one of these methods has its flaws in terms of techniques, skills, resources and costeffectiveness. While RT-PCR has been used as a gold standard, none of the other methods are being employed to that extent due to a lack of data and reliability [19] . However, RT-PCR is usually not fast enough, quite expensive and needs proper technical expertise, and thus, is not suitable for mass-level surveillance [20] .

An alternative approach would be loop mediated isothermal amplification (LAMP) that like PCR detects the viral nucleic acids, with the advantage of the capacity to test at the field level in remote areas [20] . However, major issues arise as the process relies primarily on indirect methods like turbidity and a slight color changes that can cause incorrect results and may vary from person to person in the interpretation of the result, both qualitatively and quantitatively [21] . X-rays and computed tomography (CT) are often used medically to determine the damage caused in the lungs but may not be confirmatory to COVID-19, as there are other possible causes of results resembling COVID-19, such as pneumonia, bronchitis, and other chronic obstructive pulmonary diseases (COPDs) [22] . Furthermore, the test itself suffers from expensive equipment and difficulty in the analysis of the result. Other methods such as ELISA could have been a good option, if not for the pre-requisite for a reader and skilled personnel, as well as less than ideal time to result.

All of these aforementioned issues can be avoided by using a rapid and cheap diagnostic method such as the immune-chromatographic test (ICT) in the form of RDT cassette, that can be used in the field level as well as individually, as the test is relatively easy to use, not requiring skilled laboratory professionals. In this study, we performed a prospective evaluation of a new antigen-based lateral flow, qualitative immunoassay device (OnSite ® COVID-19 Ag Rapid Test) for detection of COVID-19 in symptomatic suspected patients in urban population as well as in diagnostic center to evaluate its clinical performance and the prospects for use as a tool for early, rapid, cheap, and efficient diagnosis of COVID-19.

Consenting individuals with symptoms of COVID-19 reported to the International Center for Diarrhoeal Disease Research Bangladesh (icddr,b) laboratory services unit (LSU) in Dhaka, Bangladesh for a COVID-19 RT-PCR test between 29 April and 15 September of 2021 were considered for this study. Participants who met the study inclusion criteria (recent fever and two symptoms) were offered to participate in this study. 380 patients with evident clinical COVID-19 symptoms were enrolled in this study for testing by healthcare professionals. The study physician checked and recorded the health status of the participant in a pre-structured form.

Both nasopharyngeal and oropharyngeal samples were collected from each study participant and pooled by an expert medical technologist at the designated COVID-19 sample collection booth maintained by the LSU in a single 3 mL Viral transport medium (VTM) for RT-PCR testing. For testing on the OnSite COVID-19 Ag Rapid Test, one nasal swab was sample collected by inserting the swab up to 2 cm inside the nostril, following the product's Instruction for Use (IFU).

The OnSite ® COVID-19 Ag Rapid Test recognizes SARS-CoV-2 Nucleocapsid Protein. Using ELISA and peptide scanning, the epitopes recognized by the test have been mapped to the N-terminal domain (NTD) of the Nucleocapsid Protein. It is a lateral flow chromato-graphic immunoassay. The test cassette consists of: (1) a colored conjugate pad containing anti-SARS-CoV-2 antibodies conjugated with colloidal gold (antibody conjugates) and (2) a nitrocellulose membrane strip containing a test line (Ag line) and a control line (C line). The test line is pre-coated with anti-SARS-CoV-2 antibodies, and the C line is pre-coated with control antibodies. The OnSite ® COVID Ag rapid test was performed on the spot as per the manufacturer's IFU. Roughly in this study, a nasal swab is inserted into the nostril until resistance is met at turbinates (less than an inch to nostril) with gentle rotation several times against the nasal wall. The process is repeated in the second nostril to ensure that sample is collected, and the swab is then removed and inserted into an extraction buffer. The extracted sample is then dropped into the sample well of the cassette to finish the test procedure. When applied to the sample well, the extracted specimen migrates across the test strip by capillary action. SARS-CoV-2 antigen, if present in the extract, binds to the antibody conjugates, and the immunocomplex is then captured on the membrane by the pre-coated anti-SARS-CoV-2 antibody, forming a colored Ag line that indicates a COVID-19 positive test result. For each patient, RDT was performed immediately after sample collection, and result reading was performed at 15 min after adding the extracted sample to the test cassette.

RT-PCR testing was carried out within 24 h of sample collection by the Molecular Diagnostic Laboratory of LSU, an ISO 15189 and ISO 15190 accredited facility, and results were submitted to the national database. The test was performed targeting SARS-CoV-2 N1 and N2 genes, with human RNaseP as assay control target, after standard RNA extraction by MagMAX™ Viral/Pathogen II (MVP II) nucleic acid isolation kit using King Fisher Flex high-throughput automated extraction system (Thermo Fisher Scientific, Waltham, MA, USA). Primers recommended by Center for Disease Control (CDC) were used for the RT-PCR assay. In brief, we used Thermofisher TaqPath™ 1-Step RT-qPCR mastermix (Thermo Fisher Scientific, Waltham, MA, USA), no ROX. following a developed multiplex RT-PCR program on an ABI 7500 Fast DX instrument (Thermo Fisher Scientific, Waltham, MA, USA). 20 µL mastermix containing 5 µL of template was used for each test. The reaction condition includes steps of cDNA synthesis (10 min/55 • C), a hold step (1 min/95 • C), and subsequently 45 cycles of denaturation (10 s/95 • C) and annealing/elongation (30 s/55 • C) [23] . The threshold for a positive outcome was considered 40 amplification cycles.

For SARS-CoV-2 circulating variant screening, we sequenced spike protein using specific primer sets from ARTIC nCoV-2019 V3 panel. Among the 133 RT-PCR positive samples, 69 samples with low Ct (<27.00) values were sequenced. Sanger sequencing was performed in an automated ABI 3500 XL genetic analyzer (Applied Biosystems, Foster City, CA, USA) described elsewhere [24] . The raw sequence data were inspected by BLAST search; contigs were mapped using the SeqMan tool (DNASTAR, Inc., Software, Madison, WI, USA). The SARS-CoV-2 clade was detected using the Nextclade v1.5.2 (https://clades.nextstrain.org/ (accessed on 3 October 2021)) with default parameters [25] .

The study was approved by the institutional ethical committee (ERC) of the International Center for Diarrhoeal Disease Research, Bangladesh (icddr,b). At the time of enrollment, written informed consent was obtained from each adult participant. For the children aged 2-10 years, consent was obtained from the parents or legal guardian and in the cases of children between 11-17 years in addition to written informed consent, verbal assent was also obtained.

Data were computed in an Excel sheet. Statistical analysis was carried out using GraphPad Prism 8.0.2 (GraphPad Software, Inc., San Diego, CA, USA) and Stata version 15.1 (StataCorp, College Station, TX, USA) were used for all analysis. Paired Student's t-test was used to compare the mean and Wilcoxon rank-sum (Mann-Whitney) test was used to compare the non-normally distributed continuous data. To calculate sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) and respective confidence intervals, diagti command was used. Receiver operating characteristics (ROC) curves were built using MedCalc Statistical Software version 20.013 (MedCalc Software, Ostend, Belgium) for the analysis of sensitivity and the specificity of the RDT. A heat map was also generated to evaluate the relation among symptoms, days passed after the onset of the symptoms as well as the ability of the rapid test to detect COVID-19 at various time points.

A total of 380 individuals were enrolled where 230 (60.5%) were male with the median (IQR) age 33 (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) and 150 (39.5%) were female with the median age 32.5 (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) . There was no significant difference between median age (p = 0.26).

Out of 380 patients, 133 (35.0%) tested positives in RT-PCR where Ct values for N1 and N2 ranged from 11.0-31.7 (mean ± sd: 18.2 ± 4.7) and 11.0-36.1 (mean ± sd: 19.1 ± 5.0) respectively. The mean difference between the Ct values for N1 and N2 was significant (p < 0.001) A distribution of the RT-PCR positive patients' age in the study is shown as a violin curve (Figure 3 ). The graph indicates all age groups of patients getting infected by SARS-CoV-2.

A distribution of the RT-PCR positive patients' age in the study is shown as a violin curve (Figure 3 ). The graph indicates all age groups of patients getting infected by SARS-CoV-2. 

Overall, a symptoms-based analysis has also been displayed through the heat map in Figure 4 . Nine (9) major COVID-19 symptoms were taken into consideration with the days passed post-onset of symptoms and the number of patients in the bar associated with each heat map (Figure 4a) . Besides, the same correlation has been depicted in the heat map of Figure 4b for only the positive patients by RDT. The primary symptoms are fever, cough, sore throat, loss of smell, loss of taste, fatigue, body ache, headache, and diarrhea. The frequency of overall patient arrival and positive samples have been distributed among day 1 to day 6 and above. 

Overall, a symptoms-based analysis has also been displayed through the heat map in Figure 4 . Nine (9) major COVID-19 symptoms were taken into consideration with the days passed post-onset of symptoms and the number of patients in the bar associated with each heat map (Figure 4a) . Besides, the same correlation has been depicted in the heat map of Figure 4b for only the positive patients by RDT. The primary symptoms are fever, cough, sore throat, loss of smell, loss of taste, fatigue, body ache, headache, and diarrhea. The frequency of overall patient arrival and positive samples have been distributed among day 1 to day 6 and above.

A distribution of the RT-PCR positive patients' age in the study is shown as a violin curve (Figure 3 ). The graph indicates all age groups of patients getting infected by SARS-CoV-2. 

Overall, a symptoms-based analysis has also been displayed through the heat map in Figure 4 . Nine (9) major COVID-19 symptoms were taken into consideration with the days passed post-onset of symptoms and the number of patients in the bar associated with each heat map (Figure 4a) . Besides, the same correlation has been depicted in the heat map of Figure 4b for only the positive patients by RDT. The primary symptoms are fever, cough, sore throat, loss of smell, loss of taste, fatigue, body ache, headache, and diarrhea. The frequency of overall patient arrival and positive samples have been distributed among day 1 to day 6 and above. 

Among the 69 samples, 58 were delta (Indian) variant (84.06%), 8 beta (South African) (11.59%) variant and 3 eta (20A/S:484K probably Nigerian) variant (4.35%). The RDT could detect all the samples that were sequenced indicating the capability to detect different variants of SARS-CoV-2. The summary has been depicted in the Figure 5 . 

Among the 69 samples, 58 were delta (Indian) variant (84.06%), 8 beta (South African) (11.59%) variant and 3 eta (20A/S:484K probably Nigerian) variant (4.35%). The RDT could detect all the samples that were sequenced indicating the capability to detect different variants of SARS-CoV-2. The summary has been depicted in the Figure 5 . 

Several rapid test devices have been evaluated so far in various platforms, and most of those were conducted either with archived samples, samples preserved in VTM or a limited sample size for prospective studies [26] [27] [28] [29] [30] . In this study, we evaluated the practicality of implementing the use of the OnSite COVID-19 Ag rapid test kit as an easy-touse test to detect COVID-19. The high sensitivity and specificity of the OnSite COVID-19 Ag rapid test obtained in this study, indicate a very robust performance of the test kit. The RT-PCR positive samples that have been missed by RDT, have mostly very high Ct values (>27) (Figure 2 ). Only two samples with RT-PCR results below Ct value of 25 have been missed, which might have been a result of improper sample collection, dried nostrils or others. Supporting this hypothesis, the 12 samples that produced false negative results versus the RT-PCR assay, stored in VTM after collection for the RT-PCR assay, were later re-tested on the OnSite COVID-19 Ag rapid test, and 3 out of these 12 samples produced positive results, including the 2 RT-PCR positive samples of Ct < 25.0 in the test cassette. This could also indicate that using nasopharyngeal swab samples might result increased sensitivity compared to the nasal swab, as there is a greater chance of discharged secretion of the specimen from nasopharyngeal mucosa. As all the tests are dependent on proper sample collection, the false-negative results might have been explained by the improper discharge from respiratory mucosa or by low viral load. Only two false positive results were obtained in 380 samples, substantiating the high specificity of the OnSite COVID-19 Ag rapid test kit 99.2% (95% CI: 97.1-99.9). The false positive samples were tested with an additional RT-PCR protocol and reconfirmed as a true negative. These samples were also negative for other COVID RT-PCR target i.e., SARS-CoV-2 virus genome, E-gene, N-gene and RdRp gene [31, 32] .

A study evaluating the performance of Panbio TM COVID-19 Ag Rapid Test Device (Abbott Rapid Diagnostics, Lake Country, IL, USA) and Standard TM Q COVID-19 Ag Test (SD Biosensor, Osong, Korea) found the overall sensitivity of these kits were 89% and 

Several rapid test devices have been evaluated so far in various platforms, and most of those were conducted either with archived samples, samples preserved in VTM or a limited sample size for prospective studies [26] [27] [28] [29] [30] . In this study, we evaluated the practicality of implementing the use of the OnSite COVID-19 Ag rapid test kit as an easy-to-use test to detect COVID-19. The high sensitivity and specificity of the OnSite COVID-19 Ag rapid test obtained in this study, indicate a very robust performance of the test kit. The RT-PCR positive samples that have been missed by RDT, have mostly very high Ct values (>27) (Figure 2 ). Only two samples with RT-PCR results below Ct value of 25 have been missed, which might have been a result of improper sample collection, dried nostrils or others. Supporting this hypothesis, the 12 samples that produced false negative results versus the RT-PCR assay, stored in VTM after collection for the RT-PCR assay, were later re-tested on the OnSite COVID-19 Ag rapid test, and 3 out of these 12 samples produced positive results, including the 2 RT-PCR positive samples of Ct < 25.0 in the test cassette. This could also indicate that using nasopharyngeal swab samples might result increased sensitivity compared to the nasal swab, as there is a greater chance of discharged secretion of the specimen from nasopharyngeal mucosa. As all the tests are dependent on proper sample collection, the false-negative results might have been explained by the improper discharge from respiratory mucosa or by low viral load. Only two false positive results were obtained in 380 samples, substantiating the high specificity of the OnSite COVID-19 Ag rapid test kit 99.2% (95% CI: 97.1-99.9). The false positive samples were tested with an additional RT-PCR protocol and reconfirmed as a true negative. These samples were also negative for other COVID RT-PCR target i.e., SARS-CoV-2 virus genome, E-gene, N-gene and RdRp gene [31, 32] .

A study evaluating the performance of Panbio TM COVID-19 Ag Rapid Test Device (Abbott Rapid Diagnostics, Lake Country, IL, USA) and Standard TM Q COVID-19 Ag Test (SD Biosensor, Osong, Korea) found the overall sensitivity of these kits were 89% and 85.5%, respectively, and with specificities of 99.7% and 100% respectively [33] . Another study that evaluated the Panbio TM COVID-19 Ag Rapid Test Device found the sensitivity and specificity of 79.6% and 100%, respectively. It was found that RDT negative samples were not infectious although positive by RT-PCR. However, the number of the positives samples in this study was small (only 43 samples positive by both RT-PCR and rapid test with 11 discordant results out of 412) [34] . The Panbio TM COVID-19 Ag Rapid Test Device was also used in a prospective study with 634 asymptomatic patients in Spain, of whom Diagnostics 2021, 11, 2300 8 of 10 79 were positive, and the kit was able to detect in 48.1% cases only (38 patients) [35] . However, Standard™ Q COVID-19 Ag kit (SD Biosensor ® , Osong, Republic of Korea) was compared with RT-PCR of Allplex™ 2019-nCoV Assay (Seegene ® , Seoul, Korea) among 454 patients of which 60 people were positive and found 98.33% sensitivity. This high sensitivity might be explained by the small sample size in the study, and mainly by the low sensitivity (90%) of the RT-PCR kit, which will likely miss the low viral load samples, that would also be missed by the rapid test [36] . However, in the WHO evaluation of the SD Biosensor kit, the observed pooled sensitivity was 84.97% (130/153, 95% CI 78.3-90.23%) and the pooled specificity was 98.94% (1490/1506, 95% CI 98.28-99.39%) [37] .

From [38] . In another study, overall 79% sensitivity was obtained with area under the curve (AUC) of 0.88 with an optimal Ct cut-off value of 29 whereas in this study an AUC of 0.98 for an average cut-off value of 26.48 was obtained.

This OnSite COVID-19 Ag Rapid Test kit showed high performance in determining positive patients that came to test after 1 to >6 days from the onset of symptoms. The heat map also indicates that patients of all age groups had come to the test facility as well as that the positive samples are well distributed among the age ranges. However, fever, cough, sore throat, and body ache seemed prominent symptoms among the COVD-19 positive patients. The result also portrays its capability to detect major circulating variants of concern (VOC) as well as variants being monitored (VBM).

In the community and healthcare facilities, it often takes a significant amount of time from sample collection to RT-PCR test, from multiple hours to often even days. There is also a chance of cross-contamination of the samples that may render false-positive results when testing in batch form. One of the common pitfalls of RT-PCR is that it is also costly, and require skilled personnel along with sophisticated equipment, making it unavailable in resource-limited settings. In contrast, the OnSite COVID-19 Ag Rapid Test is a costeffective easy to use test that does not require specialized equipment or skilled laboratory personnel. Besides, there is minimal chance of cross-contamination of samples, as the kit is designed for individual patients and limits hazardous features to the operator, as the virus is inactivated by the extraction buffer media. The high sensitivity and specificity of the kit also justifies its ability to be a viable alternative to RT-PCR.

The main limitation of the rapid tests is that there is possibility of false negative results in samples with low viral load. Hence, it might not be often suitable for detection of COVID-19 in less symptomatic and asymptomatic patients.

Many countries worldwide are now shifting towards rapid Ag-based detection systems in the healthcare facilities for diagnosis of COVID-19, to reduce time as well as costs. However, RDT negative symptomatic samples should be confirmed by RT-PCR. It is likely that nasopharyngeal samples have slightly better sensitivity (92.48%) than nasal swabs only, but sample collection is less invasive to the patient when using nasal swabs. The sensitivity obtained for nasal samples should be comparable to self-testing performance at the community level, whereas nasopharyngeal sample could be an alternative for professional testing at the healthcare facilities with improved diagnostic capacity. Our study demonstrates that the OnSite COVID-19 Ag Rapid Test is a very reliable, fast, user-friendly and economic test, that can easily be implemented as the test of choice for rapid detection of COVID-19 in all sorts of healthcare facilities. Funding: This research study was funded by CTK Biotech Inc., Poway, CA, USA, grant number GR-02066. The APC will be provided by the PI of the study.

Institutional Review Board Statement: The study was approved by the institutional ethical committee (ERC) of the International Center for Diarrhoeal Disease Research, Bangladesh (icddr,b). The institutional review board (IRB) approved the study with protocol no PR-21034.

Informed Consent Statement: Written informed consent was obtained from the adult participants. For the children aged 2-10 years, consent was obtained from the parents or legal guardian and in the case of children between 11-17 years in addition to written informed consent, verbal assent was also obtained.

COVID-19 diagnosis and management: A comprehensive review

World Health Organization. WHO Coronavirus (COVID-19) Dashboard

COVID-19 Testing: The threat of false-negative results

COVID-19: Insight into the asymptomatic SARS-COV-2 infection and transmission

Asymptomatic SARS Coronavirus 2 infection: Invisible yet invincible

Challenges in ensuring global access to COVID-19 vaccines: Production, affordability, allocation, and deployment

Understanding vaccine hesitancy in COVID-19

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study

Ivermectin for preventing and treating COVID-19

Current treatment in COVID-19 disease: A rapid review. Drugs Context 2021, 10

Modes of transmission of SARS-CoV-2 and evidence for preventive behavioral interventions

Exit strategies: Optimising feasible surveillance for detection, elimination, and ongoing prevention of COVID-19 community transmission

Controlling COVID-19 Pandemic: A Mass Screening Experience in Saudi Arabia. Front

Laboratory tests for the detection of SARS-CoV-2 infection: Basic principles and examples

COVID-19 diagnosis-A review of current methods

COVID-19: Automatic detection from X-ray images utilizing transfer learning with convolutional neural networks

Mobile Health Apps that help with COVID-19 management: Scoping review. JMIR Nurs. 2020, 3, e20596

COVID-19 infection: Disease detection and mobile technology

Point-of-Care PCR Assays for COVID-19 Detection

Diagnostics for SARS-CoV-2 infections

Colorimetric RT-LAMP SARS-CoV-2 diagnostic sensitivity relies on color interpretation and viral load

Pitfalls of Computed Tomography in the Coronavirus 2019 (COVID-19) Era: A New Perspective on Ground-Glass Opacities

Detection of SARS-CoV-2 RNA by multiplex RT-qPCR

Sequencing Protocol v3 (LoCost)

Nextstrain: Real-time tracking of pathogen evolution

Evaluation of rapid antigen test for detection of SARS-CoV-2 virus

Evaluation of SARS-CoV-2 antigen-based rapid diagnostic kits in Pakistan: Formulation of COVID-19 national testing strategy

Current and innovative methods for the diagnosis of COVID-19 infection (Review)

Evaluation of rapid antigen detection kit from the WHO Emergency Use List for detecting SARS-CoV-2

Urgent need of rapid tests for SARS CoV-2 antigen detection: Evaluation of the SD-Biosensor antigen test for SARS-CoV-2

Identification of SARS-CoV-2 in a Proficiency Testing Program

AccuPower SARS-CoV-2 Multiplex RT-PCR kit (Bioneer, South Korea)" and "Allplex 2019-nCoV Assay (Seegene, South Korea)" for SARS-CoV-2 RT-PCR Diagnosis: Korean CDC EUA as a Quality Control Proxy for Developing Countries

Diagnostic accuracy of two commercial SARS-CoV-2 antigen-detecting rapid tests at the point of care in community-based testing centers

Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres

Evaluation of a rapid antigen test (Panbio™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients

Evaluation of Four Commercial Kits for SARS-CoV-2 Real-Time Reverse-Transcription Polymerase Chain Reaction Approved by Emergency-Use-Authorization in Korea

Emergency Use Assessment Coronavirus Disease (COVID-19) IVDs, PUBLIC REPORT

Evaluation of rapid SARS-CoV-2 antigen tests, AFIAS COVID-19 Ag and ichroma COVID-19 Ag, with serial nasopharyngeal specimens from COVID-19 patients

Acknowledgments: icddr:b acknowledges with gratitude the commitment of CTK Biotech Inc to its research efforts. icddr,b is also grateful to the Governments of Bangladesh, Canada, Sweden and the UK for providing core/unrestricted support.

The authors declare no conflict of interest.